Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Chipscreen Biosciences

Drug Profile

Research programme: small molecule therapeutics - Chipscreen Biosciences

Alternative Names: CS 3158; CS 410; CS 510; CS-00018; CS-00088; CS-00098; CS-12328; CS-12629; CS00028; CS0220; CS0230; CS0240; CS0600; HDAC inhibitors - Chipscreen; Histone deacetylase inhibitors - Chipscreen Biosciences; Kinase inhibitors - Chipscreen Bioscience; VEGFR inhibitors - Chipscreen Biosciences

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antihyperglycaemics; Antineoplastics; Cardiovascular therapies; Hepatoprotectants; Neuroprotectants; Small molecules
  • Mechanism of Action HDAC1 protein inhibitors; HDAC2 protein inhibitors; Histone deacetylase inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Janus kinase 3 inhibitors; MAP kinase kinase kinase 5 inhibitors; Peroxisome proliferator-activated receptor agonists; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; Retinoid X receptor agonists; Tryptophan oxygenase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Neurodegenerative disorders; Non-alcoholic fatty liver disease; Solid tumours; Type 2 diabetes mellitus
  • Discontinued Viral infections

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in China
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in China
  • 28 Oct 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top